

DARE TO DEFINE

the hallmarks of your patient's tumour

Testing for biomarkers of impaired DNA damage repair can open the opportunity for LYNPARZA to your patients*

Prescribing information

INDICATION: LYNPARZA (olaparib) is indicated for the treatment of adult patients with advanced-stage ovarian cancer who have recurrent platinum-based platinum-sensitive relapsed ovarian cancer. LYNPARZA is also indicated for the treatment of adult patients with advanced-stage relapsed pancreatic cancer who have previously received platinum-based platinum-sensitive relapsed pancreatic cancer. LYNPARZA is also indicated for the treatment of adult patients with advanced-stage relapsed pancreatic cancer who have previously received platinum-based platinum-sensitive relapsed pancreatic cancer. LYNPARZA is also indicated for the treatment of adult patients with advanced-stage relapsed pancreatic cancer who have previously received platinum-based platinum-sensitive relapsed pancreatic cancer.

CONTRAINDICATIONS: LYNPARZA is contraindicated in patients with known hypersensitivity to any of the components of LYNPARZA or to any of the excipients. LYNPARZA is also contraindicated in patients with known hypersensitivity to any of the components of LYNPARZA or to any of the excipients.

WARNINGS: LYNPARZA may cause fetal harm. Advise patients of the potential risks to the fetus. LYNPARZA may cause fetal harm. Advise patients of the potential risks to the fetus. LYNPARZA may cause fetal harm. Advise patients of the potential risks to the fetus.

See summary of product characteristics for details on prescribing information and clinical trials. For more information, please contact AstraZeneca at medinfo@astrazeneca.com.

©2021 AstraZeneca plc. All rights reserved. AstraZeneca, the AstraZeneca logo, DARE TO DEFINE, LYNPARZA, and Lynparza are trademarks of AstraZeneca plc. All other trademarks are the property of their respective owners.

Why test for biomarkers of impaired DNA damage repair?

-  Impaired ability to repair DNA damage is associated with increased risk of cancer.
-  The frequency of DNA damage repair is influenced by genetic factors.
-  BRCA1/2 mutations are associated with impaired DNA damage repair.
-  PARP1/2 mutations are associated with impaired DNA damage repair.

Biomarkers of impaired DNA damage repair help identify patients who may be eligible for LYNPARZA*

DNA damage repair and PARP inhibition

Alterations in HDR caused by gene mutations can lead to HRD which is characterized by genomic instability and impaired ability to repair DNA damage*

An understanding of the role of DNA damage repair (DDR) can help to identify patients who may be eligible for LYNPARZA. Alterations in HDR can lead to HRD which is characterized by genomic instability and impaired ability to repair DNA damage.



Your partner in precision medicine across tumour types

LYNPARZA is supported by the broadest ongoing clinical trial programme of any PARPi, across patients with biomarkers of DNA damage repair**

-  Ovarian Cancer
-  Breast Cancer
-  Pancreatic Cancer
-  Prostate Cancer

DARE TO DEFINE

Open the opportunity for LYNPARZA by supporting the appropriate for your patient*

OVARIAN CANCER A STRONG CASE FOR PARPi IN COMBINATION WITH PLATINUM	KEY FINDING: IMPROVED OVERALL SURVIVAL
BREAST CANCER LYNPARZA IS AN EFFECTIVE THERAPY FOR HRD POSITIVE BREAST CANCER PATIENTS. TEST FOR BRCA1/2 AND HRD BEFORE TREATMENT.	KEY FINDING: IMPROVED OVERALL SURVIVAL
PANCREATIC CANCER A STRONG CASE FOR PARPi IN COMBINATION WITH PLATINUM	KEY FINDING: IMPROVED OVERALL SURVIVAL
PROSTATE CANCER LYNPARZA IS AN EFFECTIVE THERAPY FOR HRD POSITIVE PROSTATE CANCER PATIENTS.	KEY FINDING: IMPROVED OVERALL SURVIVAL

**In order to fully benefit from precision medicine with LYNPARZA, we strongly encourage patients to test for biomarkers of DNA damage repair (DDR) and HRD to identify patients who may be eligible for LYNPARZA. For more information, please contact AstraZeneca at medinfo@astrazeneca.com.



Scan the QR code to access the full Lynparza Prescribing Information.

AstraZeneca
AstraZeneca Singapore Pte Ltd
10 Raffles Avenue #12-10, Raffles Tower 2, Singapore
238610 Tel: +65 6812 6700 Fax: +65 6286 2650
For Healthcare Professionals Only
S/C 46832 Date of Approval: 26/06/2020